ORCHPHARMA vs ZIMLAB: Stock Comparison
ORCHID PHARMA is the larger company by market capitalisation. ORCHID PHARMA shows a higher ROE, faster revenue growth and lower leverage, while ZIM LABORATORIES shows a lower P/E and a higher ROCE. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
ORCHPHARMA leads 7; ZIMLAB leads 3 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | ORCHPHARMA | ZIMLAB |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | ORCHPHARMA | ZIMLAB |
|---|---|---|
| Live Price | ₹860.25 | ₹135 |
| Day Change | -3.71% | -1.13% |
| Volume | 33,274 | 36,223 |
| 52-Week High | ₹1,143.5 | ₹159.81 |
| 52-Week Low | ₹480 | ₹59.31 |
| Distance from 52W High | -24.77% | -15.52% |
Valuation
| Metric | ORCHPHARMA | ZIMLAB |
|---|---|---|
| Market Cap | ₹5,161 Cr | ₹721 Cr |
| P/E Ratio | 424.19x | 176.58x |
| P/B Ratio | 2.9x | 2.42x |
| EPS | ₹0.64 | ₹-0.75 |
| Book Value | ₹308.43 | ₹55.31 |
| Dividend Yield | 0% | 0% |
Growth
| Metric | ORCHPHARMA | ZIMLAB |
|---|---|---|
| Revenue Growth (TTM YoY) | -1.5% | -3.36% |
| EPS Growth (TTM YoY) | 0% | -47.01% |
| Qtr Sales Growth | 0% | 0% |
| Qtr Profit Growth | 0% | 0% |
Profitability & Leverage
| Metric | ORCHPHARMA | ZIMLAB |
|---|---|---|
| ROE | 3.3% | 1.97% |
| ROCE | 3.77% | 4.11% |
| Net Margin | 2.51% | 1.56% |
| Operating Margin | 7.2% | 5.72% |
| Debt to Equity | 0.13x | 0.42x |
Shareholding
As of Sep 2026 • change vs previous quarter| Metric | ORCHPHARMA | ZIMLAB |
|---|---|---|
| Promoter Holding | 74.45%▲ 4.61 pp | 30.3%▼ 0.06 pp |
| FII Holding | 0.93%▲ 0.12 pp | 0.17%▲ 0.14 pp |
| DII Holding | 17.44%▼ 3.31 pp | 1.19%▼ 0.14 pp |
| Public Holding | 7.18%▼ 1.43 pp | 68.34%▲ 0.06 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ORCHID PHARMA and ZIM LABORATORIES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.